|
|
|
CARACAS, Venezuela Venezuela's trade minister says the government plans to annul the pharmaceutical patents for an antibiotic produced by Bayer HealthCare. The Venezuelan Trade Ministry said in a statement that the government...
Findings from the Phase III EINSTEIN-Extension study will be presented in the Late Breaking Abstract Session on December 8, 2009, (7:30 am EST, Hall F, Ernest N. Morial Convention Center) at the 51st Annual Meeting of the...
NEW YORK, Nov. 20 /PRNewswire/ -- GLOBAL MARKET OVERVIEW AND OUTLOOK 4 A Quick Primer On Imaging Agents 4 Growth Drivers 5 Growth Inhibitors 5 Changing Dynamics of Imaging Agents 6 Imaging Agents: Significant Growth Ahead 7...
A study of patients exposed to gadolinium contrast dyes at the Mayo Clinic has revealed that hemodialysis patients had a 77-fold higher risk of developing nephrogenic systemic fibrosis (NSF), while kidney transplant patients...
Accumetrics, Inc., developer of the VerifyNow System, the first point-of-care method for measuring platelet reactivity, announces that its market-leading VerifyNow P2Y12 Test was one of multiple methods evaluated in the POPular...
Published Friday, November 20, 2009 Carol Hsin/Contributing Photographer Of West Campus’ four entrance gates, one of which is shown above, two are employee-only, one is used by delivery trucks and one is for the public. WEST...
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company?s maytansinoid Targeted Antibody Payload...
Wendy R. Fleishman of the national plaintiffs? law firm Lieff Cabraser Heimann & Bernstein, LLP announced that Mae Walker today filed a personal injury lawsuit against Bayer Healthcare Pharmaceuticals, Inc., for severe and...
UBS said in a note â??we believe that future outperformance of Bayer is limitedâ?? following the release of third-quarter results, â??but for Air Liquide we see an upcoming positive catalystâ?? on Dec. 7, when the company holds...
In another sign of growing opposition to high cancer-drug prices, a U.K. regulator Thursday said Britain's state health system shouldn't pay for the liver-cancer drug Nexavar, calling its price tag "simply too high."
